MX2009014247A - Compuestos heterociclicos utiles como inhibidores de mk2. - Google Patents
Compuestos heterociclicos utiles como inhibidores de mk2.Info
- Publication number
- MX2009014247A MX2009014247A MX2009014247A MX2009014247A MX2009014247A MX 2009014247 A MX2009014247 A MX 2009014247A MX 2009014247 A MX2009014247 A MX 2009014247A MX 2009014247 A MX2009014247 A MX 2009014247A MX 2009014247 A MX2009014247 A MX 2009014247A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- heterocyclic compounds
- compounds useful
- ways
- symbols
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
La presente invención describe compuestos tetracíclicos de la fórmula (lA) o (!B): (ver fórmulas (IA) e (IB)) en donde los símbolos R, X, A, Y, R2, R3 y D son como se definen en la memoria descriptiva, su uso en el tratamiento de ciertas enfermedades, por ejemplo, dependientes de la actividad de MK-2 o TNF, y sus formas de fabricación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07112549 | 2007-07-16 | ||
PCT/EP2008/059158 WO2009010488A1 (en) | 2007-07-16 | 2008-07-14 | Heterocyclic compounds useful as mk2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009014247A true MX2009014247A (es) | 2010-01-28 |
Family
ID=38792023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009014247A MX2009014247A (es) | 2007-07-16 | 2008-07-14 | Compuestos heterociclicos utiles como inhibidores de mk2. |
Country Status (15)
Country | Link |
---|---|
US (2) | US7838674B2 (es) |
EP (1) | EP2178874A1 (es) |
JP (1) | JP2010533674A (es) |
KR (1) | KR20100031619A (es) |
CN (1) | CN101687869A (es) |
AR (1) | AR067535A1 (es) |
AU (1) | AU2008277676A1 (es) |
BR (1) | BRPI0814426A2 (es) |
CA (1) | CA2693904A1 (es) |
CL (1) | CL2008002073A1 (es) |
EA (1) | EA201000100A1 (es) |
MX (1) | MX2009014247A (es) |
PE (1) | PE20090480A1 (es) |
TW (1) | TW200904818A (es) |
WO (1) | WO2009010488A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8494544B2 (en) * | 2009-12-03 | 2013-07-23 | Osocad Remote Limited Liability Company | Method, apparatus and computer program to perform location specific information retrieval using a gesture-controlled handheld mobile device |
CN104710423A (zh) * | 2009-12-14 | 2015-06-17 | 默沙东有限责任公司 | Mk2抑制剂 |
AU2014277711B2 (en) * | 2009-12-14 | 2016-10-27 | Merck Sharp & Dohme B.V. | MK2 inhibitors |
US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
EP2619181A1 (en) | 2010-09-23 | 2013-07-31 | Syngenta Participations AG | Novel microbiocides |
ES2602791T3 (es) * | 2011-01-26 | 2017-02-22 | Nerviano Medical Sciences S.R.L. | Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa |
JP5925808B2 (ja) * | 2011-01-26 | 2016-05-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用 |
WO2012117021A2 (en) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Novel microbiocidal oxime ethers |
BR112013028895A2 (pt) | 2011-05-10 | 2016-08-09 | Bayer Ip Gmbh | (tio)carbonilamidinas bicíclicas |
WO2013092460A1 (en) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Cyclic bisoxime microbicides |
EP2641901A1 (en) | 2012-03-22 | 2013-09-25 | Syngenta Participations AG. | Novel microbiocides |
KR101561330B1 (ko) | 2012-09-19 | 2015-10-16 | 주식회사 두산 | 인돌로인돌계 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
CN102936216B (zh) * | 2012-12-05 | 2015-03-04 | 南京药石药物研发有限公司 | 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法 |
NO2953942T3 (es) | 2013-02-06 | 2018-03-24 | ||
KR20210091832A (ko) * | 2013-03-15 | 2021-07-22 | 셀젠 카르 엘엘씨 | Mk2 억제제 및 이의 용도 |
MA40534B1 (fr) | 2014-09-17 | 2021-04-30 | Celgene Car Llc | Inhibiteurs de mk2 et leurs utilisations |
CN105348263B (zh) * | 2015-12-15 | 2018-03-23 | 乐普药业股份有限公司 | 一种达比加群酯中间体的制备方法 |
EA201992153A1 (ru) | 2016-10-05 | 2020-02-25 | Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. | Гетероарилтрифторборатные соединения для лечения микобактериальных инфекций |
MX2019010642A (es) | 2017-03-16 | 2019-10-17 | Celgene Car Llc | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. |
US11230551B2 (en) | 2017-03-16 | 2022-01-25 | Celgene Car Llc | Deuterated analogs of MK2 inhibitors and uses thereof |
US11098057B2 (en) | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
US11124525B2 (en) | 2017-03-16 | 2021-09-21 | Celgene Car Llc | Heteroaryl compounds useful as MK2 inhibitors |
AU2018236286B2 (en) | 2017-03-16 | 2022-02-17 | Bristol-Myers Squibb Company | Forms and compositions of a MK2 inhibitor |
CN107383026B (zh) * | 2017-06-29 | 2019-04-30 | 武汉药明康德新药开发有限公司 | 一种7-羟甲基-2,5-二氮杂螺[3,4]辛烷-2-甲酸叔丁酯的合成方法 |
CN109336890B (zh) * | 2018-11-17 | 2020-03-20 | 重庆文理学院 | 一种吲唑类衍生物的合成方法及抗肿瘤应用 |
CN109678879A (zh) * | 2019-02-27 | 2019-04-26 | 陕西科技大学 | 一种苯并噻吩并吡喃酮类化合物及其合成方法 |
CN109678878A (zh) * | 2019-02-27 | 2019-04-26 | 陕西科技大学 | 一种苯并噻吩并香豆素类化合物及其合成方法 |
CN110563726A (zh) * | 2019-07-23 | 2019-12-13 | 上海合全药业股份有限公司 | 叔丁基-7,9-二氧亚基-2,6-二氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法 |
WO2023025298A1 (zh) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070236A2 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia Italia S.P.A. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
EP1572682A4 (en) * | 2002-12-20 | 2008-01-23 | Pharmacia Corp | ACYCLIC PYRAZOLE COMPOUNDS |
-
2008
- 2008-07-14 CA CA2693904A patent/CA2693904A1/en not_active Abandoned
- 2008-07-14 MX MX2009014247A patent/MX2009014247A/es not_active Application Discontinuation
- 2008-07-14 JP JP2010516479A patent/JP2010533674A/ja active Pending
- 2008-07-14 WO PCT/EP2008/059158 patent/WO2009010488A1/en active Application Filing
- 2008-07-14 KR KR1020107001022A patent/KR20100031619A/ko not_active Application Discontinuation
- 2008-07-14 AR ARP080103021A patent/AR067535A1/es unknown
- 2008-07-14 EA EA201000100A patent/EA201000100A1/ru unknown
- 2008-07-14 CN CN200880022905A patent/CN101687869A/zh active Pending
- 2008-07-14 AU AU2008277676A patent/AU2008277676A1/en not_active Abandoned
- 2008-07-14 EP EP08786115A patent/EP2178874A1/en not_active Withdrawn
- 2008-07-14 PE PE2008001178A patent/PE20090480A1/es not_active Application Discontinuation
- 2008-07-14 BR BRPI0814426-5A2A patent/BRPI0814426A2/pt not_active Application Discontinuation
- 2008-07-15 TW TW097126806A patent/TW200904818A/zh unknown
- 2008-07-15 CL CL2008002073A patent/CL2008002073A1/es unknown
- 2008-07-16 US US12/174,324 patent/US7838674B2/en not_active Expired - Fee Related
-
2010
- 2010-09-13 US US12/880,473 patent/US20120022030A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR067535A1 (es) | 2009-10-14 |
BRPI0814426A2 (pt) | 2015-01-06 |
CL2008002073A1 (es) | 2009-02-20 |
KR20100031619A (ko) | 2010-03-23 |
CN101687869A (zh) | 2010-03-31 |
TW200904818A (en) | 2009-02-01 |
AU2008277676A1 (en) | 2009-01-22 |
US20090098218A1 (en) | 2009-04-16 |
JP2010533674A (ja) | 2010-10-28 |
US7838674B2 (en) | 2010-11-23 |
WO2009010488A1 (en) | 2009-01-22 |
PE20090480A1 (es) | 2009-05-24 |
EA201000100A1 (ru) | 2010-08-30 |
US20120022030A1 (en) | 2012-01-26 |
CA2693904A1 (en) | 2009-01-22 |
EP2178874A1 (en) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009014247A (es) | Compuestos heterociclicos utiles como inhibidores de mk2. | |
TW200942533A (en) | Pyridyl inhibitors of hedgehog signalling | |
MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
MX315135B (en) | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors | |
HK1155452A1 (en) | 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors syk jak 26---5-yl- | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
EA201170521A1 (ru) | Новые соединения | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
WO2007097981A3 (en) | Alpha carbolines and uses thereof | |
TW200700064A (en) | Novel compounds | |
MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
TNSN08191A1 (en) | Kinase inhibitors | |
LTC2805723I2 (lt) | Kladribino režimas, skirtas išsėtinei sklerozei gydyti | |
IL274522A (en) | 2,6-diamino-pyrimidin-5-yl-carboxamides as inhibitors of SYK or JAK kinases | |
TW200634013A (en) | Quinoline derivative, its use, production and pharmaceutical agents containing the derivative | |
ZA200801332B (en) | Pentacyclic kinase inhibitors | |
DOP2006000233A (es) | Inhibidores de cinasa | |
MX2010001303A (es) | Compuestos terapeuticos. | |
WO2007127173A3 (en) | Therapeutic compounds | |
EP1957121A4 (en) | SEVERE TREATMENT OF SOCIAL PHOBIA | |
HU0600490D0 (en) | Medical use of chelidonium mejs, gacid, cinadane | |
GB0610486D0 (en) | Effluent treatment | |
GB0508411D0 (en) | Treatment of tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |